We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint | Next Generation Neurology

Antisense Oligonucleotides for Duchenne Muscular Dystrophy Why No Neurologist Should Skip This

Ryan D. Jacobson, MD1; Eva L. Feldman, MD, PhD1,2
[+] Author Affiliations
1Department of Neurology, University of Michigan, Ann Arbor
2A. Alfred Taubman Medical Research Institute, University of Michigan, Ann Arbor
JAMA Neurol. 2016;73(3):259-260. doi:10.1001/jamaneurol.2015.4011.
Text Size: A A A
Published online


This Viewpoint discusses the use of exon skipping therapies eteplirsen and drisapersen in Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) was described by the disease’s namesake in the mid-19th century. Over time, the phenotype, genetics, and pathogenesis of this fatal disorder of muscle degeneration have been well described. An understanding of DMD has become universally taught in medical schools and common knowledge among neurologists, physiatrists, and other physicians. Despite our now long-standing understanding of the disease, the development of new, meaningful treatments for these patients has been disappointing. The standard of care remains corticosteroids; however, this may evolve in the near future, as promising new therapies for DMD focusing on exon skipping have been described. Understanding these new therapies highlights both the exciting future of neuromuscular medicine yet also underscores significant challenges ahead. Moreover, the emergence of these treatments recently spurred the US Food and Drug Administration (FDA) to draft guidance for industry in the realm of developing drugs for treating dystrophinopathies.1

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles